MedTrace Logo

Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

NCT00585117 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-12-13

No results posted yet for this study

Summary

Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission

Conditions

Interventions

PROCEDURE

PET-imaging with CuATSM

imaging with CuATSM

PROCEDURE

PET Imaging

Imaging with CuATSM

PROCEDURE

PET CuATSM

Imaging with CuATSM

PROCEDURE

PET imaging

imaging with CuATSM

PROCEDURE

PET imaging with CuATSM

Imaging with CuATSM

PROCEDURE

PET imaging with CuATSM

Imaging with CuATSM

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Robert Jeraj, Ph.D · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585117 on ClinicalTrials.gov